Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) shares saw strong trading volume on Thursday . 546,091 shares traded hands during trading, a decline of 18% from the previous session’s volume of 662,731 shares.The stock last traded at $3.29 and had previously closed at $3.41.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. HC Wainwright assumed coverage on shares of Anthera Pharmaceuticals in a research note on Friday, July 8th. They set a “buy” rating and a $10.00 price objective on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 30th. Finally, FBR & Co reaffirmed a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Anthera Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $9.58.

The firm’s 50-day moving average price is $3.36 and its 200 day moving average price is $3.49. The stock’s market cap is $134.85 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.01. Equities research analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.26) earnings per share for the current fiscal year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.